Proteomic investigations into resistance in colorectal cancer

Cantor, David; Cheruku, Harish R.; Westacott, Jack; Shin, Joo‐Shik; Mohamedali, Abidali; Ahn, Seong Beom

doi:10.1080/14789450.2020.1713103

Cited by 13 publications

(11 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapy resistance is a frequent cause of tumor recurrence and treatment failure of cancer patients [163,164]. Uptake of CAFs-derived exosomes by cancer cells has been linked to this response.…”

Section: Therapy Resistancementioning

confidence: 99%

Cancer associated-fibroblast-derived exosomes in cancer progression

et al. 2021

View full text Add to dashboard Cite

To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells and cancer associated fibroblasts (CAFs), which communicate with cancer cells and each other during tumor progression. CAFs are a dominant and heterogeneous cell type within the TME with a pivotal role in controlling cancer cell invasion and metastasis, immune evasion, angiogenesis and chemotherapy resistance. CAFs mediate their effects in part by remodeling the ECM and by secreting soluble factors and extracellular vesicles. Exosomes are a subtype of extracellular vesicles (EVs), which contain various biomolecules such as nucleic acids, lipids, and proteins. The biomolecules in exosomes can be transmitted from one to another cell, and thereby affect the behavior of the receiving cell. As exosomes are also present in circulation, their contents can also be explored as biomarkers for the diagnosis and prognosis of cancer patients. In this review, we concentrate on the role of CAFs-derived exosomes in the communication between CAFs and cancer cells and other cells of the TME. First, we introduce the multiple roles of CAFs in tumorigenesis. Thereafter, we discuss the ways CAFs communicate with cancer cells and interplay with other cells of the TME, and focus in particular on the role of exosomes. Then, we elaborate on the mechanisms by which CAFs-derived exosomes contribute to cancer progression, as well as and the clinical impact of exosomes. We conclude by discussing aspects of exosomes that deserve further investigation, including emerging insights into making treatment with immune checkpoint inhibitor blockade more efficient.

show abstract

Section: Therapy Resistancementioning

confidence: 99%

Cancer associated-fibroblast-derived exosomes in cancer progression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Similarly to Chauvin et al., we used FFPE biopsies as well as the AJCC system for patient grouping, with a GelC‐MS/MS proteomic approach. FFPE tissues were preferred as they allow access to archival samples, usage of larger cohorts and more robust analyses, facilitating the access to follow‐up data of patients’ clinical conditions [8].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have attempted to identify candidate predictive biomarkers for response to nCRT in rectal cancer using a proteomics approach for analysis of tumor tissue [4][5][6]. However, there is scarce data in the literature about proteomic profiles of rectal cancer tissue before and after nCRT [7][8][9]. The aim of our study was to profile the proteome of rectal cancer prior to nCRT and after the treatment and to determine differentially expressed proteins between responders and non-responders in order to identify a set of candidate molecules for prediction and follow-up of response to nCRT.…”

Section: Introductionmentioning

confidence: 99%

Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non‐responders' tumor tissue

Babic

Lygirou

Rosić

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose: In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT.

show abstract

“…Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related death worldwide ( Bray et al, 2018 ; Cantor et al, 2020 ). It is estimated that by the year of 2030, CRC may account for one in every ten cancer cases and deaths, and increase the global health burden by 60% ( Bray et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics

Rao

Wan

Tou

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a growing public health concern due to its high mortality rate. Currently, there is a lack of valid diagnostic biomarkers and few therapeutic strategies are available for CRC treatment, especially for advanced CRC whose underlying pathogenic mechanisms remain poorly understood. In the present study, we investigated the serum samples from 20 patients with stage III or IV advanced CRC using data-independent acquisition (DIA)-based proteomics and ultra-performance liquid chromatography coupled to time-of-flight tandem mass spectrometry (UPLC-TOF-MS/MS) metabolomics techniques. Overall, 551 proteins and 719 metabolites were identified. Hierarchical clustering analysis revealed that the serum proteomes of advanced CRC are more diversified than the metabolomes. Ten biochemical pathways associated with cancer cell metabolism were enriched in the detected proteins and metabolites, including glycolysis/gluconeogenesis, biosynthesis of amino acids, glutathione metabolism, and arachidonic acid metabolism, etc. A protein-protein interaction network in advanced CRC serum was constructed with 80 proteins and 21 related metabolites. Correlation analysis revealed conserved roles of lipids and lipid-like molecules in a regulatory network of advanced CRC. Three metabolites (hydroquinone, leucenol and sphingomyelin) and two proteins (coagulation factor XIII A chain and plasma kallikrein) were selected to be potential biomarkers for advanced CRC, which are positively and significantly correlated with CEA and/or CA 19–9. Altogether, the results expanded our understanding of the physiopathology of advanced CRC and discovered novel potential biomarkers for further validation and application to improve the diagnosis and monitoring of advanced CRC.

show abstract

Proteomic investigations into resistance in colorectal cancer

Cited by 13 publications

References 107 publications

Cancer associated-fibroblast-derived exosomes in cancer progression

Cancer associated-fibroblast-derived exosomes in cancer progression

Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non‐responders' tumor tissue

Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics

Contact Info

Product

Resources

About